The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
DHL and other logistics companies were already transporting pharmaceutical products at minus 70°C in Schaumaplast boxes packed with dry ice before the coronavirus pandemic
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
The commercial production in the SML was started in November 1989.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
